Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3070-3076

  Holmes, Chris E ^a,b   Huang, Joe C ^a   Pace, Thomas R ^a   Howard, Alan B ^b   Muss, Hyman B ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; ENDOSTATIN; EXEMESTANE; LETROZOLE; TAMOXIFEN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; TUMOR VASCULARIZATION; BLOOD; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; IMMUNOASSAY; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); SECRETION; THROMBOCYTE;

ADULT; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ASPIRIN; BLOOD PLATELETS; BREAST NEOPLASMS; ENDOSTATINS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION INHIBITORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 49649099963     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4640     Document Type: Article

References (34)

1. Engels K, Fox SB, Whitehouse RM, et al. Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 1997;181:207-12.
2. Burstein HJ, Kindsvogel K, Parker LM, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005;94:S6.
3. Miller K, Wang M, Gralow J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
4. Miller KD, Cobleigh MA, Marcom PK, et al. Phase III trial of capecitabine plus bevacizumab versus capeci-tabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane. Breast Cancer Res Treat 2002;76:S37.
5. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-14.
6. Gasparini G. Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
7. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821 -6.
8. Weidner N, Folkman J, Pozza F, et al. Tumor angio-genesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
9. Salgado R, Benoy I, Bogers J, et al. Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 2001; 4:37-43.
10. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
11. Teh SH, Hill AD, Lee AW, et al. Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 2004;116:165-71.
12. Kuroi K, Tanaka C, Toi M. Circulating levels of endostatin in cancer patients. Oncol Rep 2001;8:405-9.
13. Daly ME. Makris A, Reed M, et al Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003;95:1660-73.
14. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the mi-croenvironment. Breast Cancer Res 2003;5:140-6.
15. Verheul HM, Hoekman K, Luykx-de Bakker S, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997;3:2187-90.
16. Jayachandran M, Miller VM. Human platelets contain estrogen receptor α caveolin-1 and estrogen receptor associated proteins. Platelets 2003;14:75-81.
17. Khetawat G. Faraday N. Nealen ML, et al. Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): testosterone regulates AR expression. Blood 2000;95:2289-96.
18. Mora L, Reineri S, Piranda D, et al. Nongenomic effects of 17β-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor β and Src kinase. Blood 2005;105:115-21.
19. Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vase Biol 2001;21:6-12.
20. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60:2898-905.
21. Buteau-Lozano H, Ancelin M, Lardeux B, et al. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors α and β Cancer Res 2002;62:4977-84.
22. Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 2002;9:39-42.
23. Coskun U, Gunel N, Sancak B, et al. Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients Ciin Exp Immunol 2004 137 546-51.
24. Fersis N, Smyczek-Gargya B. Armeanu S, et al Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer Eur J Gynaecol Oncol 2004;2:45-50.
25. Belloc C. Lu H, Soria C. et al The effect of platelets on invasiveness and protease production of human mammary tumor cells. Int J Cancer 1995;60:4137.
26. Aigner S, Sthoeger ZM, Fogel M, et al: CD24, a mu cm-type glycoprotein, is a ligand for P-selectin on human tumor cells Blood 1997:89:3385 - 95
27. Caine GJ, Lip GY, Stonelake PS, et al Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92:185-90.
28. Nierodzik ML, Klepfish A, Karpatkin S Role of platelets, thrombin, integrin llb-llla, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995;74:282-90.
29. Vitseva O, Flockhart DA. Jin Y. et al. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates J Pharmacol ExpTher 2005;312:1144-50.
30. Miller ME. Thorpe SL, Dores GM Influence of hormones on platelet intracellular calcium Thromb Res 1995;77:515-30.
31. Italiano JE. Jr., Richardson JL, Patel-Hett S. et al Angiogenesis is regulated by a novel mechanism pro- and antiangiogenic proteins are organized into separate platelet α granules and differentially released Blood 2008;111:1227-33.
32. Ma L, Perini R. McKnight W, et al Proteinase-acti- vated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 2005;102:216-20.
33. Colleoni M. Rocca A, Sandn MT et al. Low dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels Ann Oncol 2002;13:73-80.
34. Verheul HM, Pinedo HM The importance of platelet counts and their contents in cancer Clin Cancer Res 2003;9:3219-21.